Fairmount Funds Management
$1.4B Assets Reported
14 Holdings
Latest filing 2026-03-31
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| DMRA | DAMORA THERAPEUTICS INC | 8,713,000 | $226M | 16.3% |
| DNTH | DIANTHUS THERAPEUTICS INC | 2,537,191 | $213M | 15.4% |
| COGT | COGENT BIOSCIENCES INC | 5,503,418 | $212M | 15.3% |
| SYRE | SPYRE THERAPEUTICS INC | 4,018,101 | $203M | 14.6% |
| ORKA | ORUKA THERAPEUTICS INC | 3,705,262 | $182M | 13.1% |
| VRDN | VIRIDIAN THERAPEUTICS INC | 3,914,458 | $77M | 5.5% |
| ELVN | ENLIVEN THERAPEUTICS INC | 1,855,644 | $73M | 5.3% |
| JBIO | JADE BIOSCIENCES INC | 4,553,494 | $64M | 4.6% |
| CBIO | CRESCENT BIOPHARMA INC. | 2,747,866 | $50M | 3.6% |
| ZBIO | ZENAS BIOPHARMA INC | 2,359,025 | $46M | 3.3% |
Track Fairmount Funds Management's 13F portfolio: $1.4B in reported holdings, 14 positions. Top holdings, AUM, and quarterly changes on SentiSense.